Education
Case Report: Case 13
Case Presenters
Dr. Gisel Artuso, MD, Obtained her medical degree from Facultad de Ciencias Médicas, Universidad de Cuyo, in Argentina. She is currently superior resident at Instituto Zaldivar in Mendoza, Argentina, and collaborates with scientific
research activities at the Paediatric Ophthalmology and Strabismus Department in the same institution.
Dr. Liliana Laurencio, MD, Obtained her medical degree from Facultad de Ciencias Médicas, Universidad de Cuyo, in Argentina. She completed her residency in Ophthalmology at Hospital Central and then a fellowship in Paediatric Ophthalmology and Strabismus with Dr. Elena Mulet, MD, supported by Universidad de Cuyo in Mendoza. She was a medical consultant at Hospital Dr. Humberto Notti from 1993 to 2008. She was the President at Asociación Mendocina de Oftalmología from 2012 to 2015. She is currently the Chief of the Paediatric Ophthalmology and Strabismus Department and the Director of the Residency at Instituto Zaldivar. She is also Professor at Universidad de Mendoza.
Status: CASE CLOSED
Members’ Responses:
1) Which of these genes do you expect to be mutated in this case?
a) PAX6, PITX2, CYP1B1, FOXC1
b) KRT3, KRT12, TGFBI, SLC4A11
c) COL8A2, ZEB1, TACSTD2, TGFBI
While 90.32% replied they would expect the ‘PAX6, PITX2, CYP1B1, FOXC1’ gene to be mutated, 5.38% said ‘KRT3, KRT12, TGFBI, SLC4A11’ & the remaining 4.30% replied ‘COL8A2, ZEB1, TACSTD2, TGFBI’.
2) Which of these would you consider as differential diagnosis in this case?
a) Sclerocornea
b) Endothelial dystrophy
c) Dermoid
d) Rubella
e) All of them
13.68 % replied Sclerocornea, 28.42 % replied Endothelial dystrophy, 0.0% said Dermoid, 7.37% replied saying Rubella & the remaining 50.53% said All of them.
3) Would you recommend surgery for visual rehabilitation (cornea / lens) now, age 7 months?
a) Yes
b) No
54.26% said Yes & 45.74% said No.
Experts Opinion
Dr. Ken Nischal
Dr. Kanwal Nischal, better known as Ken Nischal is the Division Chief, Pediatric Ophthalmology, Strabismus, and Adult Motility Professor of Ophthalmology at the University of Pittsburgh, School of Medicine. He is also the Vice Chair, Department of Ophthalmology in addition to being the Associate Director of International Business – Ophthalmology & the Director of the Pediatric Program Development at the UPMC Eye Center.
Dr. Nischal attended King’s College Hospital Medical School, University of London and completed his Ophthalmology residency at the Oxford Eye Hospital in the United Kingdom. He completed his fellowship at The Hospital for Sick Children in Toronto, and prior to joining Children’s in 2011, he was at Great Ormond Street Hospital for Children, London in the United Kingdom.
Dr. Nischal is a pioneer in Pediatric Anterior Segment disease and surgery. He has described innovative surgical techniques, disease classification and management algorithms. He is evidence based and protocol driven in terms of clinical practice, and uses clinical audit to define management outcomes.
1) Which of these genes do you expect to be mutated in this case?
a) PAX6, PITX2, CYP1B1, FOXC1 The term Peters anomaly was coined by Peters in the late 1800’s and he described central congenital corneal opacity due to either iridocorneal adhesions or keratolenticular adhesion. This case shows neither. The term Peters anomaly is a SIGN and not as diagnosis; looking for genetic causes of a sign is not logical. In order to decide what genetic testing should be done, the accompanying ocular and systemic features should be looked for. E.g. if the child has maxillary hypoplasia and an umbilical hernia, then I would expect FOXC1 or PITX2 (if the child is small for age and has the above two features then PITX2 is more likely and an MRI of the pituitary should be done. If the child had aniridia (she does not) then I would look for PAX6 but before then I would do a renal USS to ensure no kidney masses. There is a condition called CYP1B1 cytopathy where the child gets congenital glaucoma and corneal opacity BUT the UBM does not look like this. The lens in options b and c are most commonly associated with corneal dystrophies and this is not a dystrophy. Note: it is ALWAYS important in children like this to get a cardiac and renal evaluation. 1.
2) Which of these would you consider as differential diagnosis in this case?
NONE OF THESE. Sclerocornea is a non-entity and only means total corneal opacification which this child does not have (see: Nischal KK, Naor J, Jay V, MacKeen LD, Rootman DS. Clinicopathological correlation of congenital corneal opacification using ultrasound biomicroscopy. Br J Ophthalmol. 2002 Jan;86(1):62-9.). Endothelial dystrophies that present at birth are CHED, PPMD and XL-ECD. NONE of them look like this (see: Weiss JS, Møller HU, Aldave AJ, Seitz B, Bredrup C, Kivelä T, Munier FL, Rapuano CJ, Nischal KK, Kim EK, Sutphin J, Busin M, Labbé A, Kenyon KR, Kinoshita S, Lisch W. IC3D classification of corneal dystrophies-edition 2. Cornea. 2015 Feb;34(2):117-59.) This is NOT a dermoid and rubella keratopathy never looks like this.
3) Would you recommend surgery for visual rehabilitation (cornea/lens) now, age 7 months?
This would depend entirely on a number of factors, especially the results of visual electrophysiology which will give a measure of the child’s visual potential – see below. However, if VEP is not available based on the clinical description we would recommend bilateral PKP but not at the same sitting.
4) Would you proceed in a different way in this case?
Yes. While Peters anomaly is a popular terminology many papers and studies have shown it to be used too erroneously. Describing a developmental corneal opacity as being “Peters’ anomaly” is akin to diagnosing someone with a respiratory problem as having a cough. It is a sign and not a diagnosis (see: Nischal KK. A new approach to the classification of neonatal corneal opacities. Curr Opin Ophthalmol. 2012 Sep;23(5):344-54.) The intraocular pressure is reported as elevated at 31-35mmHg, however the method of measurement is critical in these cases. Rebound tonometry over an area of corneal opacity or thickening will be falsely elevated. How was the IOP measured? Was the child awake or under anesthesia? Are there any other signs to support a diagnosis of glaucoma? An axial length of 17mm is normal at 7 weeks of age, so there is no axial elongation. What is the horizontal corneal diameter? What is the pachymetry? Are there other clinical signs to suggest iridotrabecular dysgenesis? Was medical therapy trialled to control the IOP prior to trabeculectomy? Was cyclodiode laser considered? On the other hand, at 6 months of age, an axial length of 21mm and 22mm, growing from 17mm at birth, suggests uncontrolled glaucoma despite a measured IOP of 17mmHg (again, how this was measured is important). Is there any view of the optic disc?
5) Would you consider Cyclo-G-6 to control IOP in this patient?
Yes. Cyclodiode laser is an excellent method of controlling raised IOP in infants, it provides temporary control and can be repeated multiple times. It should be performed under UBM guidance to definitively identify the location of the ciliary body, which may be challenging in cases of anterior segment dysgenesis using transillumination alone. (see: Way AL, Nischal KK. High-frequency ultrasound-guided transscleral diode laser cyclophotocoagulation. Br J Ophthalmol. 2014 Jul;98(7):992-4.)
6) UBM findings
The UBM shows that the lens is formed and there is no keratolenticular or iridocorneal attachment, suggesting that the congenital corneal opacity is primary and not secondary. It is not possible to comment on corneal thickening without pachymetry measurement or calipers on the image. It appears that the cornea is in fact thin centrally in the area of the opacity, and the peripheral cornea (which is clinically clear) may be of normal thickness.
The anterior lens reflectivity may be normal for age and not necessarily indicate the presence of cataract.
7) What would you do with the corneal opacity?
a) Corneal graft (PK) at this age; Possibly, depending on visual potential. Visual electrophysiology would help to guide further visual rehabilitation. If there is severe macular pathway dysfunction on the VEP, further surgery would be unlikely to improve visual function. b) Rotational autokeratoplasty. No – the corneal opacities are large and in the central cornea, therefore rotational keratoplasty is not a feasible option. Furthermore, the anterior chamber is shallow, so one would want to oversize a donor graft by 1mm to ‘create space’ in the anterior chamber. c) Limbal stem cell transplantation. No – the child does not have limbal stem cell failure. Furthermore, our group has specifically studied this and we found that almost all children with the phenotype shown in this case had limbal stem cell function (see: Nischal KK, Lathrop KL. The Palisades of Vogt in Congenital Corneal Opacification (An American Ophthalmological Society Thesis). Trans Am Ophthalmol Soc. 2016 Aug;114:T8.) d) Wait (In this case, until when?) No – if surgical intervention were to be considered, it would have to be now. The child is now 7 months old and has a large exotropia with nystagmus, therefore the visual outcome is likely to be poor in any case. e) Other: Consider a large surgical iridectomy in one or both eyes.
Dr. Merle Fernandes
Dr. Merle Fernandes completed her under-graduate and post-graduate training at Goa Medical College, Goa and did a fellowship in Cornea and Anterior Segment at LV Pra-sad Eye Institute (LVPEI), Hyderabad. She worked in the Cornea Service at the same Institute for 3 years. Following a brief stint at the Apollo Victor Hospital in Goa, where she set up the Ophthalmology Dept, she took charge of Cornea and Anterior Segment services at LVPEI, GMR Varalakshmi campus, Visakhapatnam since 2006.
She was ap-pointed the Director of this campus in 2008. In 2014, she completed a post-doctoral fel-lowship in Ocular Surface Immunology, under the mentorship of Professor Reza Dana at Schepens Eye Research Institute, Harvard Medical School, Boston. Her main foci of interests are corneal transplantation in children, microbial keratitis and ocular surface disorders. She has several publications in peer reviewed journals and presentations at
national and international fora.
1) Which of these genes do you expect to be mutated in this case?
a) PAX6, PITX2, CYP1B1, FOXC1 In Peters anomaly, mutations have been noted in PAX6, PITX2, CYP1B1, FOXC1 genes and the condition may be sporadic or inherited in an autosomal recessive or autosomal dominant pattern. The mutations in these genes have been associated with failure of the lens vesicle to separate from the surface ectoderm. HEnce Peters anomaly has been classified into Peters Type I with iridocorneal adhesions and type II with lenticular-corneal adhesions. The former carries a better prognosis than the latter.
2) Which of these would you consider as differential diagnosis in this case?
a) Sclerocornea The closest differential diagnosis to Peters anomaly is sclerocornea which is mostly bilateral, non-progressive and asymmetric. The limbal architecture is ill-defined and the cornea cannot be differentiated from the sclera. This may be classified into isolated peripheral sclerocornea, sclerocornea with cornea plana, sclerocornea with anterior chamber cleavage anomalies or total sclerocornea. This classification has been disputed in a publication in Current opinion of ophthalmology 2012 where the authors suggested that the terminology “peripheral sclerocornea with cornea plana” should be used as the others do not correctly describe the pathology. Endothelial dystrophy is characterized by bilateral symmetrical diffuse ground glass appearance of the cornea which is markedly thickened. Dermoid is usually located inferotemporally astride the limbus but may involve the entire cornea and is elevated with histological features of dermis, hair follicles, vascularization.
3) Would you recommend surgery for visual rehabilitation (cornea / lens) now, age 7 months?
a) Yes; Surgery is recommended since the lesions are bilateral and obscuring the visual axis.
4) 1- Would you proceed in a different way in this case?
No; It is important to control IOP before doing any procedure to restore vision hence Trabeculectomy to control IOP is essential before Penetrating keratoplasty
5) Would you consider Cyclo-G-6 to control IOP in this patient?
No; This is reserved for eyes with poor visual potential. Trabeculectomy and trabeculotomy or goniotomy or trabeculectomy with MMC or a tube can be done to control IOP with variable results. However long term results of trabeculectomy are not good and patients often require additional medical therapy and a drainage device subsequently.
6) Please explain the UBM findings?
The UBM shows a thickened cornea with hyperreflectivity within the stroma suggestive of scarring. There is a defect in the posterior stroma with a high reflective membrane extending behind it and an echo free space in between. There is some hyper reflectivity in the anterior lens suggestive of anterior capsular or sub capsular cataract.
7) What would you do with the corneal opacity?
A Rotational autograft would require a greater area of clear cornea in the periphery which could be rotated into the center which is not available in this particular case. There are also issues of donor host junction disparity, irregular astigmatism and poorer long term outcomes which need to be considered. Limbal stem cell transplantation has to be considered for cases with limbal stem cell deficiency which is not present in Peters anomaly In this scenario, waiting is not an option since the opacities are large and central and hence pharmacological mydriasis may not be very effective. Though not very clear, there appears to be exotropia and there is nystagmus. Visual potential would be limited due to this and has to be explained. An alternative option is optical iridectomy which also depends on a decent amount of clear cornea in the periphery (inferior and or nasal cornea) Descemetorhexis of the central cornea has been tried in a recently published case report by Mehta et al, to enable the healthy endothelial cells from the peripheral cornea to slide over the defect and this results in gradual clearing of the cornea with time.
Dr. Gerald W. Zaidman
Dr. Gerald W. Zaidman is Professor of Clinical Ophthalmology, Director of the Cornea Service and ViceChairman of the Department of Ophthalmology at the New York Medical College, Westchester Medical Center. Dr. Zaidman graduated from the Albert Einstein College of Medicine. He completed his Ophthalmology residency at Lenox Hill Hospital and his Cornea Fellowship at the Eye & Ear Hospital, University of Pittsburgh under Dr. Stuart Brown and Dr. Bartly Mondino. Following his fellowship, he lived in Richmond, Virginia, where he was Assistant Professor of Ophthalmology and Co-Director of the Cornea Service at the Medical College of Virginia affiliated hospitals.
He also was Director of Ophthalmology at the McGuire VA Hospital. Dr. Zaidman has published over 50 peer-reviewed articles and has presented at numerous meetings as a named lecturer on issues pertaining to cornea/external diseases, keratorefractive surgery, and pediatric corneal diseases. He has received both an honor award and a senior honor award from the American Academy of Ophthalmology. He has received 7 research grants. He has traveled to many regions of the United States, Europe, and Asia as an invited guest lecturer. He has extensive experience in laser vision correction and corneal transplant surgery and has lectured at and moderated many national eye meetings.
He is on the board of the World Society of Pediatric Ophthalmology and Strabismus and is a reviewer for all the major journals in ophthalmology. Dr. Zaidman is the founder and president of the Pediatric Keratoplasty Association. Through this society, Dr. Zaidman has organized and promoted pediatric keratoplasty, an area of extreme difficulty and complexity. For many years he has been a member of the Medical Executive Board of the Eye Bank for Sight Restoration, AAPOS, AAO & ASCRS, and many more eye societies.
In my opinion the doctors were correct in their first step of controlling the intraocular pressure. However, if we want an infant with a congenital corneal opacity to develop central vision, corneal transplant surgery should be done before six months of age. Slide eight indicates that six months after the surgery the child has developed nystagmus. Therefore, the pharmacological mydriasis is not adequate for visual development.
1) Which of these genes do you expect to be mutated in this case?
I have no opinion regarding the mutated genes; by the way in my experience genetic testing has not helped much in the management of these patients
2) Which of these would you consider as differential diagnosis in this case?
Sclerocornea
3)Would you recommend surgery for visual rehabilitation (cornea / lens) now, age 7 months?
a) Yes; visual rehabilitation is required by performing a PKP
4) Would you proceed in a different way in this case?
Yes; I would have performed corneal transplant surgery soon after the pressure was controlled.
5) Would you consider Cyclo-G-6 to control IOP in this patient?
No
6) Please explain the UBM findings?
The UBM demonstrates a thinned and scarred cornea in the first eye and a thickened and scarred cornea in the second eye.
7) What would you do with the corneal opacity?
This confirms the need for corneal transplant surgery. The eye with better visual potential should have surgery now and six weeks later the other eye should have a penetrating keratoplasty.